MiNK Therapeutics (INKT) Short Interest Ratio & Short Volume

Short interest is the volume of MiNK Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 48,500 shares of INKT short. 0.49% of MiNK Therapeutics' shares are currently sold short. Learn More on MiNK Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.49% of MiNK Therapeutics' floating shares are currently sold short.

MiNK Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 48,500 shares, an increase of 18.0% from the previous total of 41,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

MiNK Therapeutics currently has issued a total of 34,700,000 shares. Some of MiNK Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. MiNK Therapeutics currently has a public float of 9,950,000 shares.

0.49% of MiNK Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to MiNK Therapeutics: Surrozen, Inc. (1.89%), Protara Therapeutics, Inc. (4.35%), Achilles Therapeutics plc (0.10%), Pluri Inc. (0.91%), Estrella Immunopharma, Inc. (0.05%), SAB Biotherapeutics, Inc. (0.34%), Brainstorm Cell Therapeutics Inc. (2.91%), Quince Therapeutics, Inc. (6.21%), OKYO Pharma Limited (0.50%), Dyadic International, Inc. (0.92%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks.

Short selling INKT is an investing strategy that aims to generate trading profit from MiNK Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for MiNK Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of INKT, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including INKT, twice per month. The most recent reporting period available is April, 15 2024.